Advancing drug development for atrial fibrillation by prioritising findings from human genetic association studies.

ABSTRACT:

Background

Drug development for atrial fibrillation (AF) has failed to yield new approved compounds. We sought to identify and prioritise potential druggable targets with support from human genetics, by integrating the available evidence with bioinformatics sources relevant for AF drug development.

Methods

Genetic hits for AF and related traits were identified through structured search of MEDLINE. Genes derived from each paper were cross-referenced with the OpenTargets platform for drug interactions. Confirmation/validation was demonstrated through structured searches and review of evidence on MEDLINE and ClinialTrials.gov for each drug and its association with AF.

Findings

613 unique drugs were identified, with 21 already included in AF Guidelines. Cardiovascular dru

SUBMITTER: Kukendrarajah K 

PROVIDER: S-EPMC11260865 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature